Gyre Therapeutics (GYRE) Equity Average (2011 - 2026)

Gyre Therapeutics (GYRE) has 16 years of Equity Average data on file, last reported at $121.5 million in Q1 2026.

• Equity Average for Q1 2026 came in at $121.5 million, up 19.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.5 million (up 19.89% YoY), and the FY2025 annual result was $102.2 million, up 81.96% from the prior year.
• Equity Average advanced to $121.5 million in Q1 2026 per GYRE's latest filing, from $104.0 million in the prior quarter.
• Over five years, Equity Average peaked at $121.5 million in Q1 2026 and troughed at $43.3 million in Q1 2022.
• A 5-year average of $81.2 million and a median of $81.4 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average sank 51.96% in 2022, then jumped 98.33% in 2024.
• A 5-year view of Equity Average shows it stood at $50.8 million in 2022, then decreased by 2.29% to $49.6 million in 2023, then surged by 98.33% to $98.4 million in 2024, then advanced by 5.63% to $104.0 million in 2025, then advanced by 16.86% to $121.5 million in 2026.
• Business Quant data shows GYRE's Equity Average at $121.5 million in Q1 2026, $104.0 million in Q4 2025, and $115.7 million in Q3 2025.